Antibodies to Tie1 ectodomain

Details Antibodies to Tie1 ectodomain Antibodies to Tie1 ectodomain

2011-01-18

2011-01-18

Spector, Lorraine (Department: 1647)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

C424S133100, C424S141100, C424S143100, C530S387100, C530S388100, C530S388150, C530S388220

Reexamination Certificate

active

07871610

ABSTRACT:
Tie1 and Tie2 are receptor tyrosine kinase proteins that include a transmembrane domain. Tie1 and Tie2 are present on endothelial cells. This disclosure describes agents, such as antibodies, that bind to Tie1, Tie2, and Ang, including ones that inhibit endothelial cell activity.

REFERENCES:
patent: 5521073 (1996-05-01), Davis et al.
patent: 5851797 (1998-12-01), Valenzuela et al.
patent: 5955291 (1999-09-01), Alitalo et al.
patent: 6090382 (2000-07-01), Salfeld et al.
patent: 6365154 (2002-04-01), Holmes et al.
patent: 6376653 (2002-04-01), Holmes et al.
patent: 6441137 (2002-08-01), Davis et al.
patent: 6492331 (2002-12-01), Godowski et al.
patent: 6551822 (2003-04-01), Godowski et al.
patent: 6586397 (2003-07-01), Godowski et al.
patent: 6627415 (2003-09-01), Davis et al.
patent: 7193064 (2007-03-01), Mikayama et al.
patent: 2002/0115173 (2002-08-01), Ben-Sasson
patent: 2002/0160478 (2002-10-01), Ben-Sasson
patent: 2003/0040463 (2003-02-01), Wiegand et al.
patent: 2003/0087393 (2003-05-01), O'Reilly et al.
patent: 2003/0113782 (2003-06-01), Karim et al.
patent: 2003/0152945 (2003-08-01), Deak et al.
patent: 2003/0162712 (2003-08-01), Cerretti et al.
patent: 2003/0166858 (2003-09-01), Davis et al.
patent: 2003/0180718 (2003-09-01), Pillutla et al.
patent: 2003/0219772 (2003-11-01), Kuyl et al.
patent: 2004/0067882 (2004-04-01), Alsobrook II et al.
patent: 2004/0116330 (2004-06-01), Naito et al.
patent: 2004/0147449 (2004-07-01), Siemeister et al.
patent: 2004/0248781 (2004-12-01), Kerbel
patent: 2006/0013449 (2006-01-01), Marschner et al.
patent: 2006/0057138 (2006-03-01), Wood et al.
patent: 1225233 (2002-07-01), None
patent: WO93/14124 (1993-07-01), None
patent: WO95/26364 (1995-10-01), None
patent: WO-95/26364 (1995-10-01), None
patent: WO-01/11086 (2001-02-01), None
patent: WO-01/47944 (2001-07-01), None
patent: WO01/72339 (2001-10-01), None
patent: WO03/094904 (2003-11-01), None
patent: WO2004/108130 (2004-12-01), None
patent: WO2005/019267 (2005-03-01), None
patent: WO2006/020706 (2006-02-01), None
patent: WO2007/095338 (2007-08-01), None
Rudikoff et al., Single acid amino acid substitution altering antigen-binding specificity. Proc. Natl. Acad. Sci., USA, 79, 1979-1983, 1982.
Kobrin et al., A V region mutation in a phosphocholine-binding monoclonal antibody results in loss of antigen binding. J. Immunol., 146, 2017-2020,1991.
Barrios et al., Length of the antibody heavy chain complementarity-determining region 3 as a specificity-determining factor. J. Molec. Recog., 17, 332-338, 2004.
Chen-Konak et al., “Transcriptional and post-translation regulation of the Tie1 receptor by fluid shear stress changes in vascular endothelial cells,” FASEB J.(2003) 17:2121-23.
Jones et al., “Tie receptors: new modulators of angiogenic and lymphangiogenic responses,” Nat Rev. Mol. Cell Biol. (Apr. 2001) 2(4):257-67.
Kontos et al., “The endothelial receptor tyrosine kinase Tie1 activates phosphatidylinositol 3-kinase and Akt to inhibit apoptosis,” Mol. Cell Biol. Mar. 2002;22(6):1704-13.
Lin et al., “Tie-1 protein tyrosine kinase: a novel independent prognostic marker for gastric cancer,” Clin. Cancer Res. (Jul. 1999) 5(7):1745-51.
Loughna and Sato, “A combinatorial role of angiopoietin-1 and orphan receptor TIE1 pathways in establishing vascular polarity during angiogenesis,” Mol. Cell (2001) 7:233-39.
Marron et al., “Tie-1 receptor tyrosine kinase endodomain interaction with SHP2: potential signallimg mechanisms and roles in angiogenesis,” Adv. Exp. Med. Biol. (2000) 476:35-46.
Marron et al., “Evidence for heterotypic interaction between the receptor tyrosine kinases TIE-1 and TIE-2,” J Biol Chem. (Dec. 2000) 15;275(50):39741-6.
Partanen et al., “A novel endothelial cell surface receptor tyrosine kinase with extracellular epidermal growth factor homology domains,” Mol. Cell Biol. (Apr. 1992) 12(4):1698-707.
Puri et al., “The receptor tyrosine kinase TIE is required for integrity and survival of vascular endothelial cells,” EMBO J. (Dec. 1, 1995) 14(23):5884-91.
Shahrara et al., “Differential expression of the angiogenic Tie receptor family in arthritic and normal synovial tissue,” Arthritis Res. (2002) 4:201-208.
Tsiamis et al., “Characterization and regulation of the receptor tyrosine kinase Tie-1 in platelets,” J. Vasc. Res. (Nov.-Dec. 2000) 37:437-42.
Blakey, David C. et al., “Antitumor Activity of the Novel Vascular Targeting Agent ZD6126 in a Panel of Tumor Models,”Clinical Cancer Research, vol. 8:1974-1983 (2002).
Davis, Samuel et al., “Isolation of Angiopoietin-1, a Ligand for the TIE2 Receptor, by Secretion-Trap Expression Cloning,”Cell, vol. 87:1161-1169 (1996).
Hurwitz, Herbert et al., “Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastic Colorectal Cancer,”The New England Journal of Medicine, vol. 350(23):2335-2342 (2004).
Partanen, Juha et al., “A Novel Endothelial Cell Surface Receptor Tyrosine Kinase with Extracellular Epidermal Growth Factor Homology Domains,”Molecular and Cellular Biology, vol. 12(4):1698-1707 (1992).
International Search Report for Application No. PCT/US04/26116, dated Nov. 2, 2007.
International Search Report for Application No. PCT/US07/81621, dated Mar. 14, 2008.
International Search Report for Application No. PCT/US05/28413, dated Aug. 8, 2006.
International Search Report for Application No. PCT/US08/50870, dated Aug. 27, 2008.
Hurwitz et al., “Bevacizumab plus Irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer”, New England Journal of Med. 350:2335-2342 (2004).
International Search Report dated Nov. 2, 2007 from International Application No. PCT/US04/26116.
Shen Juqun et al., “An antibody directed against PDGF receptor beta enhances the antitumor and the anti-angiogenic . . .” Biochem. Biophys. Res. Comm., 357(4):1142-1147 (2007).
Jo Nobuo et al., “Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial . . .” Am. J. Pathology, 168(6):2036-2053 (2006).
Dransfield et al., “100 Poster Targeting tie-1 inhibits the growth of tumor xenografts as monotheraphy and has increased activity . . .” Eur. J. Cancer. Suppl., 4(12):34 (2006).
Tol Jolien et al., “Chemotherapy, Bevacizumab and Cetuximab in Metastatic Colorectal Cancer,” New England J. Med., 360(6):563-572 (2009).

Affiliated with

Also associated with

Rating

Antibodies to Tie1 ectodomain does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antibodies to Tie1 ectodomain, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies to Tie1 ectodomain will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2651267